Today, physicians are able to target the unique nature of an individual patient’s tumor by matching treatments at the molecular level, resulting in improved outcome.
Already in 2011, a study
from MD Anderson Cancer Center found that patients with advanced cancers treated with the traditional or standard of care, which is based on their type or origin of cancer rather than their DNA tumor profile, had a mere 5% response rate to their treatment.
The same study found that when patients with metastatic cancers were treated using a personalized approach, matching them at the molecular level, there was a 27% response rate.This was the beginning of personalized medicine using DNA. OmiCure™ goes one step further using RNA and it is available now.